Cargando…

Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5)

OBJECTIVE: Advanced or recurrent endometrial cancer (EC) no longer amenable to surgery or radiotherapy is a life-threatening disease with limited therapeutic options left. Eighty percent of ECs express receptors for luteinizing hormone–releasing hormone (LHRH), which can be targeted by AEZS-108 (zop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emons, Günter, Gorchev, Grigor, Harter, Philipp, Wimberger, Pauline, Stähle, Anne, Hanker, Lars, Hilpert, Felix, Beckmann, Matthias W., Dall, Peter, Gründker, Carsten, Sindermann, Herbert, Sehouli, Jalid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2014
Materias:	Uterine Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921259/ https://www.ncbi.nlm.nih.gov/pubmed/24418927 http://dx.doi.org/10.1097/IGC.0000000000000044

Ejemplares similares

Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125
por: Seitz, Stephan, et al.
Publicado: (2014)

The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma
por: Fodor, Klara, et al.
Publicado: (2020)

LHRH analogues and breast cancer.
por: Korkut, E., et al.
Publicado: (1991)

Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer
por: Visapää, Harri
Publicado: (2017)

LHRH agonists and the prevention of breast and ovarian cancer.
por: Pike, M. C., et al.
Publicado: (1989)

Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels
por: Popovics, Petra, et al.
Publicado: (2014)

Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer
por: Szabó, Zsuzsanna, et al.
Publicado: (2021)

Shrinkage of uterine fibroids by preoperative LHRH analogue injection.
por: McClelland, H. R., et al.
Publicado: (1992)

(99m)Tc-LHRH in tumor receptor imaging
por: Hao, Dawei, et al.
Publicado: (2017)

Improving ovarian cancer imaging with LHRH-NBs: an experimental study
por: Li, Wenjuan, et al.
Publicado: (2016)

Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors
por: Curtis, Kelly K., et al.
Publicado: (2014)

LHRH analogues in breast cancer: clever, but do we need them?
por: Smith, I. E.
Publicado: (1991)

Synthesis of Radiolabeled Technetium- and Rhenium-Luteinizing Hormone-Releasing Hormone ((99m)Tc/Re-Acdien-LHRH) Conjugates for Targeted Detection of Breast Cancer Cells Overexpressing the LHRH Receptor
por: Calderon, Lindsay E., et al.
Publicado: (2021)

Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture
por: Wilson, Hannah C.P., et al.
Publicado: (2015)

Subclinical leprosy manifesting as a reversal reaction after LHRH agonist administration
por: Carmo, R.L.M.L., et al.
Publicado: (2018)

Preoperative Tumor Size at MRI Predicts Deep Myometrial Invasion, Lymph Node Metastases, and Patient Outcome in Endometrial Carcinomas
por: Ytre-Hauge, Sigmund, et al.
Publicado: (2015)

Increased Association Between Endometriosis and Endometrial Cancer: A Nationwide Population-Based Retrospective Cohort Study
por: Yu, Hann-Chin, et al.
Publicado: (2015)

Prior Tubal Ligation Might Influence Metastatic Spread of Nonendometrioid Endometrial Carcinoma
por: Li, Mingxia, et al.
Publicado: (2016)

Should the Optimal Adjuvant Treatment for Patients With Early-Stage Endometrial Cancer With High-Intermediate Risk Factors Depend on Tumor Grade?
por: Lan, Chunyan, et al.
Publicado: (2015)

Comparison of Survival Benefits of Combined Chemotherapy and Radiotherapy Versus Chemotherapy Alone for Uterine Serous Carcinoma: A Meta-analysis
por: Lin, Yanying, et al.
Publicado: (2017)

Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma
por: Wang, Fangfang, et al.
Publicado: (2017)

Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model
por: Taurin, Sebastien, et al.
Publicado: (2018)

The Use of Endometrial Cancer Patient–Derived Organoid Culture for Drug Sensitivity Testing Is Feasible
por: Girda, Eugenia, et al.
Publicado: (2017)

Possible Risk Factors of Pulmonary Metastases in Patients With International Federation of Gynecology and Obstetrics Stage I Endometrioid-Type Endometrial Cancer
por: Jiang, Wei, et al.
Publicado: (2017)

From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents.
por: Corbin, A.
Publicado: (1982)

Analogues of LHRH versus orchidectomy: comparison of economic costs for castration in advanced prostate cancer.
por: Rutqvist, L. E., et al.
Publicado: (1992)

Antitumor effects of cecropin B-LHRH’ on drug-resistant ovarian and endometrial cancer cells
por: Li, Xiaoyong, et al.
Publicado: (2016)

Small molecule targeted NIR dye conjugate for imaging LHRH receptor positive cancers
por: Roy, Jyoti, et al.
Publicado: (2019)

Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer
por: Ndinguri, Margaret, et al.
Publicado: (2023)

Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial
por: Ohlmann, Carsten-Henning, et al.
Publicado: (2017)

Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.
por: Philip, P. A., et al.
Publicado: (1993)

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma
por: Treszl, Andrea, et al.
Publicado: (2013)

Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes
por: He, Yingna, et al.
Publicado: (2010)

Glutaric acid as a spacer facilitates improved intracellular uptake of LHRH–SPION into human breast cancer cells
por: Kumar, Challa SSR, et al.
Publicado: (2007)

TAT-LHRH conjugated low molecular weight chitosan as a gene carrier specific for hepatocellular carcinoma cells
por: Liu, Lanxia, et al.
Publicado: (2014)

Squamous cell carcinoma of the prostate following treatment with an LHRH–agonist: a rare case of transformation of adenocarcinoma of the prostate
por: Al–Qassim, Zubair, et al.
Publicado: (2014)

AB166. Recovery of spermatogenesis of KH-465 herbal extract for LHRH agonist induced male infertility in rat
por: Park, Hyun Jun, et al.
Publicado: (2015)

Gender Disparity Impacts on Thymus Aging and LHRH Receptor Antagonist-Induced Thymic Reconstitution Following Chemotherapeutic Damage
por: Hun, Michael Ly, et al.
Publicado: (2020)

SUN-063 Usefulness of a LHRH Test with Low Dose of Triptorelin Pamoate in the Diagnosis of Precocious Puberty in Girls
por: Llano, Juan Pablo, et al.
Publicado: (2020)

LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer
por: Obayemi, J. D., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ub9r5ngj68tgud0u883ua8t8s1